MECHELEN, BELGIUM--(Marketwired - April 12, 2013) - Galapagos NV (Euronext: GLPG) announced
that it has received a transparency notification pursuant to the Belgian
transparency legislation (Belgian Act of 2 May 2007 on the disclosure of
shareholdings in issuers whose shares are admitted to trading on a
market) from Gestion Deelnemingen V BV.
Galapagos received a transparency notification on 10 April 2013 from
Deelnemingen V. Gestion Deelnemingen V notified that as a result of the
share capital increase, the 1,340,000 shares they hold now represent 4.97%
the current 26,968,328 outstanding Galapagos shares.
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
with a large pipeline of four clinical, six pre-clinical, and 30 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases, about
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778,
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is
first inhibitor of FFA2 to be evaluated clinically for the treatment of
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta
Fidelta, has around 800 employees and operates facilities in five
with global headquarters in Mechelen, Belgium. Further information at:
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Gestion notify of 4.97% shareholding in Galapagos:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE